Open AccessNovel pharmacotherapies in diabetic retinopathy
Author(s) -
Vaidehi S. Dedania,
Sophie J. Bakri
Publication year - 2015
Publication title -
middle east african journal of ophthalmology (print)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.357
H-Index - 25
eISSN - 0975-1599
pISSN - 0974-9233
DOI - 10.4103/0974-9233.154389
Subject(s) - medicine , diabetic retinopathy , triamcinolone acetonide , bevacizumab , pharmacology , angiogenesis , signal transduction , oxidative stress , ctgf , ranibizumab , bioinformatics , diabetes mellitus , cancer research , ophthalmology , growth factor , endocrinology , receptor , chemotherapy , biochemistry , chemistry , biology
This is a summary of current and emerging pharmacologic therapies utilized in the treatment of diabetic retinopathy (DR). Current therapies, such as ranibizumab, bevacizumab, triamcinolone acetonide, and fluocinolone acetonide, inhibit angiogenesis and inflammation and may be used alone or in combination with laser treatment. Emerging therapies aim to reduce oxidative stress or inhibit other signal transduction pathways, including the protein kinase C cascade and aldose reductase pathway. Future therapies may target other molecules crucial to the pathogenesis of DR, including hepatocyte growth factors and matrix metalloproteinase 9. Finally, the emergence of novel mechanisms of medication delivery may also be on the horizon.